PharmaFocus Today – Page 124 – media

Merck’s PD-1 Inhibitor Pembrolizumab Receives Fourth Lung Cancer Indication Approval in China

On December 3, Merck announced that its PD-1 inhibitor Pembrolizumab (brand name: Keytruda®) has been approved by the National Medical Products Administration (NMPA) in China for use in combination with platinum-based chemotherapy for neoadjuvant treatment, followed by continued use of Pembrolizumab as monotherapy for adjuvant treatment in patients with resectable stage II, IIIA, and IIIB non-small cell lung cancer (NSCLC). Previously, Pembrolizumab had received three indications for advanced non-small cell lung cancer in China. https://finance.eastmoney.com/a/202412043259018786.html
- Source: drugdu
- 271
- December 9, 2024
Fosun Pharma’s Surufatinib Injection New Indication Approved

On December 3, Fosun Pharma announced that its subsidiary, Hansoh Pharmaceutical, has received approval from the National Medical Products Administration for the marketing authorization application of Hansou® (Surufatinib Injection) in combination with Pemetrexed and Carboplatin for the first-line treatment of unresectable locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) that is negative for epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusion. https://finance.eastmoney.com/a/202412033257905182.html
- Source: drugdu
- 156
- December 9, 2024
Rgenta Therapeutics announced a strategic collaboration with GSK to jointly develop small molecule splicing regulators targeting RNA

Rgenta will receive cash advances and pre-exercise milestone payments, and is expected to receive milestone payments, royalties and potential equity investments Rgenta Therapeutics is a clinical-stage biotechnology company dedicated to developing a series of oral small molecule drugs targeting RNA targets for the treatment of cancer and neurological diseases. The company announced today that it has signed a multi-year multi-target strategic research collaboration agreement with GlaxoSmithKline (GSK) to advance the discovery and development of new small molecule splicing regulators targeting RNA in multiple disease areas such as tumors. Dr. Christopher Austin, Senior Vice President of Research Technology at GSK, said: “We are very excited about Rgenta’s differentiated approach to discovering and developing oral small molecule splicing regulators for high-value targets. We are committed to working with industry-leading companies to further enrich our existing expertise in the field of targeted RNA drugs. At the same time, we also look forward to ...
- Source: drugdu
- 192
- December 9, 2024
Eli Lilly claims that Tilpotide is more effective than Smeaglutide

Lilly stated in a press release on December 4th that in a head to head randomized controlled trial, its weight loss drug Zepbound was more effective in weight loss than its competitor Novo Nordisk’s Wegovy. This result is not surprising for scientists and doctors who are closely monitoring the rise of glucagon like peptide-1 (GLP-1) weight loss drugs. This randomized controlled trial also reflects the results of diabetes drugs from the two companies. These drugs use the same active ingredients and are sold under the brands of Mounjaro and Ozempic respectively. Similar results have been observed in observational studies and previous clinical trials comparing drugs with placebos separately. However, recording the differences between Zepbound and Wegovy in a rigorous manner is still an important step, especially as such a comparison may allow Lilly to claim in marketing that Zepbound has better therapeutic effects. This can help Lilly win ...
- Source: drugdu
- 625
- December 7, 2024
Baumer 50 series process sensors lead the industry to new standards

In today’s rapidly accelerating industrial automation process, the performance and quality of process sensors play a crucial role in the precision, efficiency, and reliability of production. The newly launched 50 series process sensors by Bao Meng have numerous unique advantages, making them stand out among many similar products and once again attracting industry attention. The Baumer 50 series process sensors embody cutting-edge technology and innovative design concepts, with many outstanding features such as compact design, excellent performance, and easy operation. This series of high-performance sensors adheres to the consistent style of Baumer products, adopting a simple and unified operation mode, allowing operators to quickly and conveniently complete debugging work and easily get started in the subsequent use process. It covers the market tested PAC50 conductivity sensor, as well as the newly developed PT55 temperature sensor and PP56 pressure sensor. PP56 pressure sensor The PP56 pressure sensor has demonstrated an ...
- Source: drugdu
- 199
- December 7, 2024
47% more weight loss! Eli Lilly releases “single challenge” semaglutide data

On December 4, local time, Eli Lilly announced the results of the Phase 3b clinical study of SURMOUNT-5. The subjects in the weight loss version of Zepbound lost 50.3 pounds (22.8 kg) at week 72, and the subjects in the weight loss version of Wegovy lost 33.1 pounds (15 kg) during the same period. Compared with semaglutide, the average weight loss effect of Zepbound is 47% higher. SURMOUNT-5 is a multicenter, randomized, open-label, head-to-head study designed to evaluate the efficacy and safety of Zepbound and semaglutide in obese or overweight adults with at least one comorbidity such as hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, and without diabetes. A total of 751 participants were recruited in the trial and assigned in a 1:1 ratio to receive the maximum tolerated dose of tirpotide (10mg or 15mg) or semaglutide (1.7mg or 2.4mg). At 72 weeks, the average weight loss ...
- Source: https://mp.weixin.qq.com/
- 445
- December 7, 2024
1 “Parkinson’s new drug” approved for marketing

According to the official website of NMPA, Zambon/Parexel Pharmaceuticals’ Safinamide Mesylate Tablets have been approved for marketing. According to public information, Safinamide is a drug used to treat Parkinson’s disease. Parkinson’s disease is the second most common neurodegenerative disease and a common activity disorder. Its main cause is a lack of dopamine. According to statistics, about 1-2% of people over 65 years old suffer from Parkinson’s disease worldwide. In China, there are more than 3 million Parkinson’s disease patients, and the incidence rate increases with age. It is predicted that the number of Parkinson’s patients in China will exceed 5 million in 2030. The “OFF” period is a common phenomenon in the middle and late stages of Parkinson’s disease. Patients usually show severe aggravation of symptoms such as muscle stiffness, tremor and movement difficulties. According to statistics, about 75% of Parkinson’s patients in the middle and late stages will ...
- Source: https://news.yaozh.com/archive/44631.html
- 378
- December 7, 2024
A local pharmaceutical company’s road to overtaking on a curve

At the end of 2011, the first drug of ranibizumab entered the Chinese market. As a biological drug for the treatment of fundus macular degeneration, it has a monopoly advantage in the market and is priced at nearly 10,000 yuan per bottle. Originally, multinational pharmaceutical companies wanted to make a fortune from this star product in the huge Chinese market, but no one could have imagined that a Chinese local company that “sticks to its research and development” – Kanghong Pharmaceutical would overtake others and bring down the price of the drug in one fell swoop… A pioneering journey of “a narrow escape from death” In 1994, Kanghong was established in the wave of reform and opening up. This innovative pharmaceutical company started with traditional Chinese medicine. Its Songling Xuemaikang Capsule is an exclusive patented Chinese medicine for the treatment of hypertension and primary hyperlipidemia. At the same time, in ...
- Source: https://news.yaozh.com/archive/44633.html
- 342
- December 7, 2024
Siemens Healthineers collaborates with the ‘Third Party Imaging Leader’

On December 1st, Siemens Healthineers and DeepHealth officially announced a major strategic partnership, with the latter partnering with Siemens Healthineers to implement SmartTechnology by embedding AI driven health informatics into workflows and imaging hardware ™， Bringing innovative changes to the field of ultrasound operations. Data shows that DeepHealth is a wholly-owned subsidiary of RadNet, a global leader in AI driven health informatics, dedicated to providing AI driven health informatics to achieve breakthroughs in the nursing field through imaging. RadNet is also the largest third-party independent medical imaging company in the United States. 01. DeepHealth collaborates with Siemens Healthineers At present, the high-capacity ultrasound nursing environment is facing severe challenges such as labor shortage, operator limitations and fatigue, and unstable image acquisition quality. These problems may not only delay accurate diagnosis, but also lead to unnecessary examination processes. In response to this situation, the remote collaboration and image acquisition command center ...
- Source: drugdu
- 221
- December 6, 2024
Toshiba to lay off another 3000 employees

Recently, according to authoritative financial media such as Kyodo News, legendary giant Toshiba is planning to implement a large-scale layoff in Japan, with an expected number of layoffs exceeding 3000, accounting for about 5% of its total Japanese employees. Toshiba further stated that this round of layoffs will mainly target employees aged 50 and above, and will be carried out through voluntary resignation. For employees who choose to resign before the end of November this year, the company will provide additional severance pay and promise to provide a two-year re employment support service to alleviate their worries. It is worth noting that this is not the first time Toshiba has taken large-scale layoffs this year. As early as May this year, Toshiba announced that it would lay off up to 5000 employees in Japan, accounting for about 6%, with the aim of accelerating the restructuring process and reducing costs to ...
- Source: drugdu
- 151
- December 6, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.